[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617034":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":41,"responsibleParty":58,"collaborators":26,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":26,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":26,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":81,"overallStatus":44,"whyStopped":26,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"University of Sao Paulo General Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Control","ACTIVE_COMPARATOR","Clonazepam 0,25 mg",[13],"Drug: clonazepam 0,25 mg",{"label":15,"type":16,"description":17,"interventionNames":18},"Intervention","EXPERIMENTAL","Clonidine 0,1 mg",[19],"Drug: clonidine",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","clonidine","Clonidine 0,1 mg bid",[15],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"clonazepam 0,25 mg","clonazepam 0,25 mg bid",[9],[32],{"name":33,"affiliation":34,"role":35},"Dangela Lassi","University of São Paulo General Hospital","PRINCIPAL_INVESTIGATOR",[37],{"name":33,"role":38,"phone":39,"phoneExt":26,"email":40},"CONTACT","+551138032802","dangela.lassi@hc.fm.usp.br",[42],{"facility":43,"status":44,"city":45,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Instituto Perdizes","RECRUITING","São Paulo","05021-001","Brazil","BR",{"type":50,"coordinates":51},"Point",[52,53],-46.63611,-23.5475,{"lat":53,"lon":52},[56],{"name":57,"role":38,"phone":39,"phoneExt":26,"email":40},"DANGELA LASSI",{"type":35,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Dângela Layne Silva Lassi","Coordinator","100617034","phase-4-efficacy-of-clonidine-in-reducing-craving-in-inpatients-with-cocaine-and-crack-use-disorder-100617034",false,"NCT07313371","Efficacy of Clonidine in Reducing Craving in Inpatients With Cocaine and Crack Use Disorder","Efficacy of Clonidine in Reducing Craving in Inpatients With Cocaine and Crack Use Disorder: a Randomized Clinical Trial.","Inclusion Criteria:\n\n* Patients hospitalized in the adult Alcohol and Drugs ward of the Perdizes Institute (IPer) at the Hospital das Clínicas, University of São Paulo Medical School\n* DSM-5 criteria for cocaine and\u002For crack use disorder\n* Voluntarily seeking treatment\n* Must be able to swallow pills\n\nExclusion Criteria:\n\n* Inability to read and\u002For understand the study questionnaires\n* benzodiazepine use disorder\n* opioid use disorder\n* alcohol use disorder","ALL","18 Years","65 Years",{"count":72,"type":73},36,"ESTIMATED","INTERVENTIONAL",[76],"PHASE4","This is a single-center, randomized intervention study in a volunteer population of patients with cocaine\u002Fcrack use disorder to evaluate the pharmacological treatment of cocaine\u002Fcrack craving, comparing the drug clonidine with the active placebo clonazepam.",[79,80],"Cocaine Use Disorder","Crack Abuse or Dependence",[82,83,84],"crack","cocaine","craving","2026-02-20",{"date":87,"type":88},"2026-02-24","ACTUAL",{"date":90,"type":88},"2026-01-28",{"date":92,"type":73},"2027-07",{"name":5,"class":6},1]